View PDF Edition - U.S. Pharmacist

More documents

Recommendations

Info

Generic Trends“Free Generic Fill”Provision in HealthCare ReformLegislationApplauded by GPhA“GPhA applauds theSenate Finance Committeefor approving the‘Free Generic Fill’ provision[in health carereform legislation],which would savepatients and the federalgovernment more than$6 billion over 10years,” commentedKathleen Jaeger, presidentand CEO of theGeneric PharmaceuticalAssociation (GPhA).The “free generic fill”provision creates anexception that wouldallow health plan sponsorsto encourage beneficiariesto utilize genericdrugs by allowing themto waive copays as anincentive to try a genericdrug.“Clearly, Congress hasrecognized that expandingaccess to genericmedicines is the key tolowering health carecosts...,” said Jaeger.Innovative PharmacyBenefit PlanDesign Can OptimizeGeneric UtilizationData from research conductedby CVS Caremarkand presented at theAcademy of ManagedCare Pharmacy (AMCP)Annual Educational Conferenceshowed that innovativepharmacy benefitplan design can impactgeneric utilization. Specifically,the study foundthat implementing a $0copay structure forgeneric medications canbe an effective strategy toincrease generic dispensing,with the generic dispensingrate increasing to60.8% (which representsa 4.2% increase).“The data presented atAMCP illustrate anexample of how we canwork with our plan sponsorsto change and optimizeparticipant behaviorin order to achieveincreased generic utilization,”said Jack Bruner,executive vice president,CVS Caremark.Some other datauncovered by the studyshowed that the averageparticipant cost share forgeneric medicationsdecreased almost 10%and the average plan costper 30 days of therapyalso exhibited a slightdecline, despite thereduction in genericcopayment rates.Call for PapersU.S. Pharmacist is seeking authors to write clinical articles and continuing education lessons on a variety of topics. While we willentertain all subject matter, we are particularly interested in articles that correspond to our “Editorial Focus” therapeutic areas. Thetherapeutic categories and the months for which they are planned are listed below:Cardiovascular Diseases – FebruaryEndocrinology – JuneGastroenterologic Diseases – DecemberInfectious Diseases – AugustNeurologic Diseases – JanuaryNew Drugs – OctoberOphthalmology – AprilPain Management – MayPediatric and Adolescent Health – MarchPsychotropics – NovemberRespiratory Diseases – JulyWomen’s Health – SeptemberIn addition to these topics, we also publish supplements each yearcovering oncology and hematology, diabetes, the generic drugindustry, and OTC drugs.In the majority of cases, articles are peer-reviewed and an honorariumis offered based on their complexity and length. As a generalguideline, we would like the articles to be approximately 2,500–2,800 words, including references and tables. Continuingeducation lessons should be approximately 6,000 words, includingreferences, tables, and exam. Prospective authors are urged toreview the “Author Guidelines” on the U.S. Pharmacist Web siteat www.uspharmacist.com.Interested authors should contact Rob Davidson, Executive Editor(rdavidson@jobson.com), with the topic(s) they would like to cover.All articles must be original and exclusive to U.S. Pharmacist.
GREENSTONELLCWatch Our Product LineGREENSTONELLCWhat Greenstone Offers YouNew and progressive business modelLeading generic-industry supplierIndustry and corporate integrityDedicated supply-chain expertiseCommitted to quality in every doseMarket support — when other supplierscan’t supplyRapidly growing product portfolioAuthorized generics and ANDA productsCompetitive pricingAND…Uncompromising g commitmentto serviceRecently IntroducedANDA Products• Amoxicillin Tablets• Bisoprolol Fumarate Tablets• Cefadroxil Capsules• Cefdinir Capsules• Cefprozil Tablets• Cefuroxime Axetil Tablets• Lamotrigine Tablets• Levetiracetam Tablets• Ondansetron HCl Tablets• Topiramate TabletsAuthorized Generic Products• Alprazolam Tablets• Alprazolam XR Tablets• Amlodipine Besylate Tablets• Azithromycin: Tablets & Powderfor Oral Suspension• Clindamycin HCl Capsules• Colestipol HCl Micronized Tablets• Eplerenone Tablets• Fluconazole: Tablets & Powderfor Oral Suspension• Gabapentin: Capsules & Tablets• Glipizide XL Tablets• Sulfasalazine DR Tablets• Sulfasalazine Tablets• Triazolam Tablets... and MoreGREENSTONELLC800-447-3360www.GreenstoneLLC.comGST00073© GREENSTONE LLC 2009 GSP I04
Page 5 and 6:
USE IN SPECIFIC POPULATIONSPregnanc
Page 7 and 8:
U.S. PharmacistWhat’s NewsEditori
Page 9 and 10:
Q. Which Global Generic Company’s
Page 11 and 12:
If key productsare missing from you
Page 13 and 14:
1,500+ WaysWe Meet Your Needs
Page 15 and 16:
✁PATIENT INFORMATIONCombating Fat
Page 17 and 18:
Consult Your Pharmacistsleep, wheth
Page 19 and 20:
PATIENT TEACHING AIDBipolarDisorder
Page 21 and 22:
Our most important ingredient is in
Page 23 and 24:
IN THE TREATMENT OF MRSA BACTEREMIA
Page 25 and 26:
SCHIZOPHRENIA: A REVIEW OF TREATMEN
Page 28 and 29:
SCHIZOPHRENIA: A REVIEW OF TREATMEN
Page 30 and 31:
HEALTH SYSTEMS EDITION© JUPITERIMA
Page 32 and 33:
FENTANYL TRANSDERMAL SYSTEMBRIEF SU
Page 34 and 35:
other opioids, or to subtract the f
Page 36: TRAUMATIC BRAIN INJURYHEALTH SYSTEM
Page 40 and 41: HEALTH SYSTEMS EDITIONNewly Approve
Page 42 and 43: HEALTH SYSTEMS EDITIONMTOR INHIBITO
Page 48 and 49: HEALTH SYSTEMS EDITIONIn-Service Pr
Page 50 and 51: NUTRITION AND CLINICAL DEPRESSIONHE
Page 52 and 53: NUTRITION AND CLINICAL DEPRESSIONHE
Page 54: NUTRITION AND CLINICAL DEPRESSIONHE
Page 57 and 58: PROGRESSIVE SUPRANUCLEAR PALSYlabil
Page 60 and 61: FDA Fast FactsNew LeukemiaTreatment
Page 62: So Many Options,So Little Differenc
Page 66: WHAT IS THE APPROPRIATE ANTIDEPRESS
Page 75 and 76: WHAT IS THE APPROPRIATE ANTIDEPRESS
Page 77 and 78: OPIOID MAINTENANCE TREATMENTTable 1
Page 79 and 80: KAPIDEX is the first and only PPI w
Page 81 and 82: Nursing Mothers
Page 83 and 84: Table 3Potential Drug Interactions
Page 85: Providing Affordable andInnovative
Page 89 and 90: Contemporary Compoundinglevel in le
Page 91 and 92: PHARMACOLOGIC MANAGEMENT OF ALCOHOL
Page 93 and 94: Zmax: 1 product — indicated for b
Page 95 and 96: PHARMACOLOGIC MANAGEMENT OF ALCOHOL
Page 97 and 98: CRIMINALIZATION OF MEDICATION ERROR
Page 99 and 100: &are excited to launch:www.PharmQD.
Page 101 and 102: Table 1Early Barriers PreventingUti
Page 103 and 104: EMERGENCY CONTRACEPTION: AN UPDATEo
Page 105 and 106: EMERGENCY CONTRACEPTION: AN UPDATEs
Page 107 and 108: EMERGENCY CONTRACEPTION: AN UPDATE1
Page 109 and 110: Examination Answer SheetCredits: 2.
Page 111 and 112: U.S. Pharmacist ClassifiedsCAREER O
Page 113 and 114: ONGLYZA (saxagliptin) tabletsBrief
show all

View PDF Edition - U.S. Pharmacist

Create successful ePaper yourself

Delete template?

Save as template?